ENTA PEER ANALYSIS

Enanta Pharmaceuticals Inc — metric-by-metric comparison with peers and the industry median

ENTAEnanta Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

ENTAIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	ENTA	MSB	RTALB	TLX	Ind. Median
P/E	—	—	4.89	—	17.91
P/B	2.77	—	0.61●	6.37	3.51
EV/EBITDA	—	—	74.61●	120.14	14.82
P/S	4.67	31.61	6.67	3.24●	10.89

Financial Health
Metric	ENTA	MSB	RTALB	TLX	Ind. Median
Current Ratio	3.84●	—	1.21	1.43	5.90
Debt/Equity	160.1%	—	1.2%●	112.3%	10.9%
NetDebt/EBITDA	-0.49●	—	0.90	13.13	1.15

Profitability
Metric	ENTA	MSB	RTALB	TLX	Ind. Median
Net Margin	-89.6%	-115.3%	136.3%●	-0.9%	-125.7%
ROE	-59.0%	-11.3%	15.1%●	-1.8%	-47.5%
ROA	-19.4%	-8.6%	13.1%●	-0.7%	-35.8%
EBITDA Margin	-67.3%	-76.6%	9.0%●	3.0%	-105.8%

Growth + Dividend
Metric	ENTA	MSB	RTALB	TLX	Ind. Median
Rev. Growth	7.4%	410.4%●	24.0%	56.3%	5.1%
NI Growth	—	—	134.0%	—	12.1%
Div. Yield	—	0.0%●	0.0%●	—	0.2%
Payout	—	0.0%	0.0%	—	0.0%

Valuation
Metric	ENTA	TRDA	ZNTL	OABI	LYEL	MGNX	Ind. Median
P/E	—	—	—	—	—	—	17.91
P/B	2.77	1.19	1.72	1.18	1.12●	14.10	3.51
EV/EBITDA	—	—	—	—	—	—	14.82
P/S	4.67	56.29	—	10.74	9,914.77	1.90●	10.89

Financial Health
Metric	ENTA	TRDA	ZNTL	OABI	LYEL	MGNX	Ind. Median
Current Ratio	3.84	13.90●	6.19	4.80	7.23	1.90	5.90
Debt/Equity	160.1%	18.4%	21.2%	7.5%●	17.9%	172.2%	10.9%
NetDebt/EBITDA	-0.49●	1.24	1.32	0.87	0.86	2.32	1.15

Profitability
Metric	ENTA	TRDA	ZNTL	OABI	LYEL	MGNX	Ind. Median
Net Margin	-89.6%	-2,895.1%	—	-187.7%	-794,858.1%	-44.8%●	-125.7%
ROE	-59.0%	-48.3%	-51.9%	-20.2%●	-80.8%	-140.3%	-47.5%
ROA	-19.4%	-40.4%	-39.0%	-18.1%●	-63.1%	-31.8%	-35.8%
EBITDA Margin	-67.3%	-2,873.3%	—	-117.0%	-770,932.3%	-32.2%●	-105.8%

Growth + Dividend
Metric	ENTA	TRDA	ZNTL	OABI	LYEL	MGNX	Ind. Median
Rev. Growth	7.4%	-96.7%	-100.0%	8.1%●	-52.3%	3.1%	5.1%
NI Growth	—	—	—	—	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on ENTA

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.